A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients

3×10E8 pfu, once q3 weeks, 3 cycles, IT

15 mg/kg/day, 14 days, 1 cycle, PO

1,200 mg, once q3 weeks, 2 cycles, IV

3×10E8 pfu, once q3 weeks, 2 cycles, IT

1×10E8 pfu, once q3 weeks, 2 cycles, IT

20 mg/kg/day, 14 days, 1 cycle, PO

25 mg/kg/day, 14 days, 1 cycle, PO

30 mg/kg/day, 14 days, 1 cycle, PO

35 mg/kg/day, 14 days q3 weeks, 2 cycles, PO

optimal dose, once q3 weeks, 2 cycles, IT

optimal dose, 14 days q3 weeks, 2 cycles, PO